Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ609,56100,25
KB677678-0,15
PKN73,6873,760,77
Msft240,6240,730,71
Nokia3,94253,9495-1,89
IBM141,05141,80,35
Daimler AG71,7771,8-1,60
PFE39,5839,6-0,25
13.05.2021 14:30:49
Indexy online
AD Index online
select
AD Index online
 

  • 12.05.2021
Biomarin Pharma (BMRN.O, NASDAQ Cons)
Závěr k 12.5.2021 Změna (%) Změna (USD) Objem obchodů (ks)
75,60 -0,12 -0,09 774 455
Premarket13.05.2021 14:22:42
Poslední obchod Nákup / Prodej Změna (%) Změna (USD) Objem obchodů (ks)
75,60 74,80 76,19 0,00 0,00 328
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 13.05.2021
Popis společnosti
Obecné informace
Název společnostiBioMarin Pharmaceutical Inc.
TickerBMRN
Kmenové akcie:Ordinary Shares
RICBMRN.O
ISIN-
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky31.03.2021
Počet zaměstnanců k 31.12.2020 3 059
Akcie v oběhu k 21.04.2021 182 742 573
MěnaUSD
Kontaktní informace
Ulice105 Digital Dr
MěstoNOVATO
PSČ94949-8703
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 155 066 700
Fax14153827889

Business Summary: BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
Financial Summary: BRIEF: For the three months ended 31 March 2021, BioMarinPharmaceutical Inc. revenues decreased 3% to $486M. Netincome decreased 79% to $17.4M. Revenues reflect Kuvan1segment decrease of 42% to $70.8M, Naglazyme1 segmentdecrease of 6% to $107.3M, United States segment decreaseof 15% to $208.2M, Latin America segment decrease of lessthan 1% to $59.7M. Net income also reflects Gain on sale ofnonfinancial assets decrease from $59.5M (income) to $0K.
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 13.05.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerJean-Jacques Bienaime65
Chief Financial Officer, Executive Vice PresidentBrian Mueller4629.06.2020
President - Worldwide Research & DevelopmentHenry Fuchs6202.03.2009
Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical OperationsC. Greg Guyer-04.05.202004.05.2020
Executive Vice President, General Counsel, SecretaryG. Eric Davis48
Executive Vice President, Chief Commercial OfficerJeff Ajer5719.12.2013
Chief Accounting Officer, Group Vice PresidentAndrea Acosta4113.07.202012.07.2020
Chief Scientific Strategy OfficerLon Cardon-07.10.201907.10.2019